Genetic burden mirrors epidemiology of multiple sclerosis by Hilven, Kelly & Goris, An
 Published as: Mult Scler. 2015 Jul 21. pii: 1352458515596603 (ahead of print)  
Invited editorial 
Genetic burden mirrors epidemiology of multiple sclerosis 
 
Kelly Hilven, An Goris 
Laboratory for Neuroimmunology, Department of Neurosciences, KU Leuven – University of Leuven, 
Herestraat 49 bus 1022, 3000 Leuven, Belgium 
 
Corresponding author: 
an.goris@med.kuleuven.be, phone +32-16-330772 
 
The prevalence of multiple sclerosis (MS) varies worldwide and, within Europe, decreases with 
latitude from Scandinavia to the Mediterranean populations. Several explanations have been offered 
for the prevalence gradient including environmental factors such as sunlight exposure. However, 
differences in the frequency of genetic risk factors may well explain an important fraction of variation 
in prevalence of MS1. The Italian island of Sardinia, one of the highest risk regions worldwide with an 
MS prevalence of 224/100,000 inhabitants, is a notable exception on the north-south gradient and is 
characterized by a genetic background distinct from other European populations and long isolation2. 
In two papers in the current issue of Multiple Sclerosis Journal, Hadjixenofontos et al. and Barizzone 
et al. investigate the combined role of known MS genetic risk factors in this special population3, 4.  
 
The current list of known MS risk variants includes several independent HLA alleles and 110 non-HLA 
variants, most of which have been identified in the context of the International Multiple Sclerosis 
Genetics Consortium, with contributions from continental Europe, the UK, US and Australia5, 6. 
Combining data from the current studies in Sardinia3, 4 with previous work in Europeans5, 6 and 
African Americans7 demonstrates that common MS risk variants tend to be shared across 
populations even though their population frequencies can vary. Indeed, the vast majority (89%) of 
non-HLA risk variants detected in a mixed European population show over-representation of the risk 
allele also in Sardinian cases versus controls, with 42% reaching nominal significance as expected in a 
single study population of this size4.  
 
A summary measure, the multiple sclerosis genetic burden (MSGB), counts the total number of MS 
risk alleles a person carries, weighted by the risk effect size of each variant. As expected and as seen 
in other European populations8, the average genetic burden in patients is higher than in controls3, 4. 
More remarkably, the genetic burden in Sardinian controls is significantly elevated compared to 
continental Italian or US controls and approximately equals the burden observed in patients in the 
latter populations3, 4. This increased burden is not due to a few variants with exceptionally deviating 
frequencies in Sardinia but rather to a subtle increase in frequency for many risk variants. This is seen 
in the median difference of 1% between the frequency of non-HLA risk variants in Sardinia and 
continental Italy4 or the average difference of 2 out of a total possible of 218 risk alleles between US 
controls and both US cases and Sardinian controls3. Barizzone et al. further extend this observation 
by reporting a correlation between the burden of known genetic variants and the prevalence of MS 
throughout Europe4. Genetic scores capturing general trends in epidemiology have already been 
shown for other immune-related diseases9. 
 
Both studies report some degree of heterogeneity between the Sardinian and mixed European 
population in the percentage of the variance explained by known variants and the distribution of the 
non-HLA burden stratified by the HLA burden3, 4. This may once again relate to differences in the 
frequency of shared risk variants, which are even more pronounced for the HLA region compared to 
non-HLA variants. Indeed, all of the five classical HLA alleles originally reported in mixed European5, 6 
or Sardinian10 populations are significantly associated with MS in both continental Italy and Sardinia4 
but frequencies and consequently the power to detect these effects in different study populations 
vary. The DRB1*1501 allele is common in northern Europe, less common in southern Europe and rare 
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in Sardinia, where the DRB1*0301 allele takes over as predominant HLA risk allele. The DRB1*0405-
DQB1*0301 risk haplotype, on the other hand, is only seen in Sardinia, continental Italy and Italian 
minorities but is virtually absent elsewhere11. Further fine-mapping of the regions of association, 
especially the HLA region for which non-additive effects and interactions have been suggested10, 12, 
will improve models of how a different frequency spectrum contributes to disease risk in Sardinia 
versus other European populations. 
 
Components of the genetic burden contribute not only to risk but also the phenotype of the disease. 
The HLA burden, especially the DRB1*1501 allele, corresponds on average to a younger age at onset5, 
8 and higher antibody production in the cerebrospinal fluid8, 13, and there are indications that a higher 
non-HLA burden, based on the up-to-date list of known variants in mainly immunological genes, 
correlates with higher relapse rate8. Hence, an intriguing question remains whether the increased MS 
genetic burden or the different frequency spectrum of especially HLA alleles within this burden 
reflects distinct features of the disease phenotype in Sardinia.  
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